Orphan play Ultragenyx raises $121M in IPO

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) raised $121 million through the sale of a bumped-up number of shares above its proposed price range in an IPO. Ultragenyx sold 5.8 million shares at $21, which values the Orphan disease company at $610.3 million. On Wednesday, Ultragenyx said it planned to sell 4.8 million shares at $19-$20. JPMorgan; Morgan Stanley; Cowen; and Canaccord are underwriters. Ultragenyx is slated to start trading Friday. ...